Amneal Pharmaceuticals, Inc. (AMRX): Cash & Equivalents
$282.03M
As of 2025-12-31
$127.64M
As of 2026-06-30
+121.4%
3-year compound annual growth
-3.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $282.03M | +155.1% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $110.55M | +20.8% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $91.54M | +252.4% | 2026-02-27, Balance as of period end |
| 2022-12-31 | $25.98M | -89.5% | 2025-02-28, Balance as of period end |
| 2021-12-31 | $247.79M | -27.4% | 2024-03-14, Balance as of period end |
| 2020-12-31 | $341.38M | +125.8% | 2023-03-03, Balance as of period end |
| 2019-12-31 | $151.20M | -29.1% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $213.39M | +187.7% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $74.17M | +171.0% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $27.37M | n/a | 2019-03-01, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $282.03M | +155.1% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | -8.3% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.31B | +39.1% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.66B | +71.5% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $618.70M | -33.4% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $801.28M | -27.4% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.39B | -42.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $545.00M | +16.5% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $984.65M | +26.3% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗